Bausch Health Companies Amends 2023 Performance Share Units (PSUs) Payout Structure for Key Executives
Bausch Health Companies Inc. (NYSE: BHC, TSX: BHC) has announced material changes regarding the settlement of its 2023 Performance Share Unit (PSU) awards for certain executives, including CEO Thomas Appio and Executive Vice President Seana Carson. This significant development was disclosed in the company’s SEC Form 8-K filing dated March 2, 2026, with the earliest event reported as February 26, 2026.
Key Points from the Report
- Change in PSU Settlement Method: The company’s Talent and Compensation Committee has amended the terms of the 2023 PSUs, originally granted in March 2023, so that they will now be paid out in cash rather than shares upon vesting.
- Impact on Named Executive Officers: This change affects major awards for two key executives:
- Thomas Appio (CEO): 1,137,862 PSUs are now set to be settled in cash. The amount each PSU is worth will be determined based on the closing price of Bausch Health’s common shares on the vesting date, March 3, 2026.
- Seana Carson (EVP): 137,922 PSUs will also be settled in cash on the same terms. Ms. Carson has agreed to irrevocably surrender her PSUs for cash, as contemplated under Canadian tax law (Income Tax Act paragraph 7(1)(b)).
- Vesting Schedule: The 2023 PSUs were granted for a three-year performance period and will vest on March 3, 2026.
- Market Price Determination: The cash payout will be based on the market price of Bausch Health’s common shares at vesting, making the value of the award directly tied to the company’s share price performance on that date.
- Disclosure and Filing: Full details of the amended and restated award agreements for Mr. Appio and Ms. Carson will be made available in the company’s Form 10-Q for the quarter ending March 31, 2026.
Shareholder-Relevant and Potentially Price-Sensitive Information
- Alignment of Incentives: By settling PSUs in cash rather than stock, the company may be seeking to reduce dilution for shareholders. This could be perceived positively by the market, as it avoids issuing new shares and could support future share price stability.
- Significant Cash Obligation: The settlement of over 1.27 million PSUs in cash (based on the number for Appio and Carson alone) represents a potentially substantial cash outflow, contingent on the company’s share price at vesting. Investors may need to consider the impact on liquidity and capital allocation.
- Tax Considerations: The specific mention of Canadian tax law in Ms. Carson’s agreement may indicate efforts to optimize tax outcomes for both the company and the executive, possibly reflecting broader changes in compensation practice for Canadian-based firms.
- Executive Compensation Transparency: The move to greater clarity and predictability in executive compensation is noteworthy. It may also reflect a response to investor feedback on equity dilution or executive pay practices.
Details of the Amended Agreements
- Appio Agreement: The amended and restated award agreement for CEO Thomas Appio covers 1,137,862 2023 PSUs. Upon vesting, these will be settled solely in cash, with the payout equal to the number of earned PSUs multiplied by the closing price of Bausch Health common stock on March 3, 2026.
- Carson Agreement: EVP Seana Carson will irrevocably dispose of her 137,922 2023 PSUs for a cash payment determined in the same manner. This is formalized in an agreement structured to comply with Canadian tax law.
- Filing and Reference: The full text of these agreements will be available in the upcoming Form 10-Q and are incorporated by reference in the current Form 8-K.
Implications for Investors
- The direct link between cash payouts and the share price at vesting aligns executive incentives with shareholder interests but also creates a material cash liability for the company.
- The change may support the share price by avoiding dilution but could raise concerns about cash management, particularly if the share price is high at vesting.
- Investors should monitor the company’s liquidity trends and any commentary on the expected cash impact during upcoming quarterly disclosures.
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. Please consult your financial advisor before making investment decisions. The author and publisher make no representations or warranties as to the accuracy or completeness of the information contained herein.
